rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACIU
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AC Immune to Present at Jefferies Global Healthcare Conference 2026
      Nov 11Yahoo FinanceACIU
      AC Immune earnings beat by CHF0.03, revenue topped estimates
      Nov 4Investing.comACIU
      AC Immune Third Quarter 2026 Financial and Corporate Update
      Nov 4Yahoo FinanceACIU
      AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceACIU
      AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals

      AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and ni

      Sep 26Yahoo FinanceACIU
      AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU)
      Sep 24Seeking AlphaACIU
      H.C. Wainwright reiterates AC Immune stock rating on trial data
      Sep 24Investing.comACIU
      AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response - AC Immune (NASDAQ:ACIU)

      AC Immune reported positive safety and immunogenicity results from Part 1 of its Phase 2 Parkinson's disease trial for ACI-7104.

      Sep 23BenzingaACIU
      AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ)
      Sep 23Seeking AlphaACIU
      AC Immune reports positive phase 2 trial results for ACI-7104
      Sep 23Investing.comACIU
      AC Immune reports positive phase 2 trial results for Parkinson’s drug
      Sep 23Investing.comACIU
      AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

      All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizationsClear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 –

      Sep 23Yahoo FinanceACIU
      AC Immune stock rating reiterated at Buy by H.C. Wainwright
      Aug 24Investing.comACIU

      This is the newest page. Registered accounts read further back.